Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
$3.8B | $0.26 | 1.17% | 49.81% | $19.33 |
|
EWCZ
European Wax Center, Inc.
|
$52.4M | $0.10 | -4.36% | -13.39% | $6.68 |
|
KMB
Kimberly-Clark Corp.
|
$4.1B | $1.75 | -16.65% | 35.35% | $127.40 |
|
SKIN
The Beauty Health Co.
|
$68.3M | -$0.05 | -7.01% | -66.08% | $1.93 |
|
SLSN
Solesence, Inc.
|
-- | -- | -- | -- | -- |
|
WALD
Waldencast Plc
|
$67.8M | -$0.11 | 18.69% | -- | $3.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
$17.21 | $19.33 | $33B | 23.13x | $0.21 | 4.79% | 2.21x |
|
EWCZ
European Wax Center, Inc.
|
$3.69 | $6.68 | $161.2M | 14.15x | $0.00 | 0% | 0.76x |
|
KMB
Kimberly-Clark Corp.
|
$101.08 | $127.40 | $33.5B | 17.12x | $1.26 | 4.99% | 1.86x |
|
SKIN
The Beauty Health Co.
|
$1.46 | $1.93 | $186.2M | -- | $0.00 | 0% | 0.62x |
|
SLSN
Solesence, Inc.
|
$1.80 | -- | $127M | 128.57x | $0.00 | 0% | 2.07x |
|
WALD
Waldencast Plc
|
$1.90 | $3.20 | $241.8M | -- | $0.00 | 0% | 0.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
46.14% | -0.989 | 29.3% | 0.58x |
|
EWCZ
European Wax Center, Inc.
|
83.03% | 4.875 | 191.37% | 2.95x |
|
KMB
Kimberly-Clark Corp.
|
84.58% | 0.061 | 18.63% | 0.37x |
|
SKIN
The Beauty Health Co.
|
85.23% | 3.884 | 149.6% | 4.02x |
|
SLSN
Solesence, Inc.
|
59.38% | 2.682 | 11.09% | 0.66x |
|
WALD
Waldencast Plc
|
20.1% | -0.517 | 29.71% | 0.53x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
$2.2B | $713M | 7.47% | 13.85% | 18.95% | $196M |
|
EWCZ
European Wax Center, Inc.
|
$34.7M | $14.3M | 3.41% | 16.45% | 26.36% | $16.5M |
|
KMB
Kimberly-Clark Corp.
|
$1.5B | $638M | 20.69% | 135.54% | 15.37% | $368M |
|
SKIN
The Beauty Health Co.
|
$45.6M | -$6.2M | -2.13% | -19.76% | -8.84% | $8.6M |
|
SLSN
Solesence, Inc.
|
$3.4M | -$781K | 2.86% | 6.62% | -5.35% | -$2.9M |
|
WALD
Waldencast Plc
|
-- | -- | -4.62% | -5.64% | -- | -- |
European Wax Center, Inc. has a net margin of 10.58% compared to Kenvue, Inc.'s net margin of 9.91%. Kenvue, Inc.'s return on equity of 13.85% beat European Wax Center, Inc.'s return on equity of 16.45%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
59% | $0.21 | $19.7B |
|
EWCZ
European Wax Center, Inc.
|
63.98% | $0.09 | $487M |
Kenvue, Inc. has a consensus price target of $19.33, signalling upside risk potential of 12.34%. On the other hand European Wax Center, Inc. has an analysts' consensus of $6.68 which suggests that it could grow by 81.12%. Given that European Wax Center, Inc. has higher upside potential than Kenvue, Inc., analysts believe European Wax Center, Inc. is more attractive than Kenvue, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2 | 11 | 0 |
|
EWCZ
European Wax Center, Inc.
|
2 | 4 | 1 |
Kenvue, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison European Wax Center, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Kenvue, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 4.79%. European Wax Center, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue, Inc. pays 150.5% of its earnings as a dividend. European Wax Center, Inc. pays out -- of its earnings as a dividend.
Kenvue, Inc. quarterly revenues are $3.8B, which are larger than European Wax Center, Inc. quarterly revenues of $54.2M. Kenvue, Inc.'s net income of $398M is higher than European Wax Center, Inc.'s net income of $5.4M. Notably, Kenvue, Inc.'s price-to-earnings ratio is 23.13x while European Wax Center, Inc.'s PE ratio is 14.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue, Inc. is 2.21x versus 0.76x for European Wax Center, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2.21x | 23.13x | $3.8B | $398M |
|
EWCZ
European Wax Center, Inc.
|
0.76x | 14.15x | $54.2M | $5.4M |
Kimberly-Clark Corp. has a net margin of 10.58% compared to Kenvue, Inc.'s net margin of 8.29%. Kenvue, Inc.'s return on equity of 13.85% beat Kimberly-Clark Corp.'s return on equity of 135.54%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
59% | $0.21 | $19.7B |
|
KMB
Kimberly-Clark Corp.
|
35.98% | $1.34 | $8.8B |
Kenvue, Inc. has a consensus price target of $19.33, signalling upside risk potential of 12.34%. On the other hand Kimberly-Clark Corp. has an analysts' consensus of $127.40 which suggests that it could grow by 26.04%. Given that Kimberly-Clark Corp. has higher upside potential than Kenvue, Inc., analysts believe Kimberly-Clark Corp. is more attractive than Kenvue, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2 | 11 | 0 |
|
KMB
Kimberly-Clark Corp.
|
3 | 10 | 1 |
Kenvue, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kimberly-Clark Corp. has a beta of 0.251, suggesting its less volatile than the S&P 500 by 74.946%.
Kenvue, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 4.79%. Kimberly-Clark Corp. offers a yield of 4.99% to investors and pays a quarterly dividend of $1.26 per share. Kenvue, Inc. pays 150.5% of its earnings as a dividend. Kimberly-Clark Corp. pays out 64.62% of its earnings as a dividend. Kimberly-Clark Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Kenvue, Inc.'s is not.
Kenvue, Inc. quarterly revenues are $3.8B, which are smaller than Kimberly-Clark Corp. quarterly revenues of $4.2B. Kenvue, Inc.'s net income of $398M is higher than Kimberly-Clark Corp.'s net income of $344M. Notably, Kenvue, Inc.'s price-to-earnings ratio is 23.13x while Kimberly-Clark Corp.'s PE ratio is 17.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue, Inc. is 2.21x versus 1.86x for Kimberly-Clark Corp.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2.21x | 23.13x | $3.8B | $398M |
|
KMB
Kimberly-Clark Corp.
|
1.86x | 17.12x | $4.2B | $344M |
The Beauty Health Co. has a net margin of 10.58% compared to Kenvue, Inc.'s net margin of -15.61%. Kenvue, Inc.'s return on equity of 13.85% beat The Beauty Health Co.'s return on equity of -19.76%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
59% | $0.21 | $19.7B |
|
SKIN
The Beauty Health Co.
|
64.59% | -$0.09 | $444.6M |
Kenvue, Inc. has a consensus price target of $19.33, signalling upside risk potential of 12.34%. On the other hand The Beauty Health Co. has an analysts' consensus of $1.93 which suggests that it could grow by 32.42%. Given that The Beauty Health Co. has higher upside potential than Kenvue, Inc., analysts believe The Beauty Health Co. is more attractive than Kenvue, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2 | 11 | 0 |
|
SKIN
The Beauty Health Co.
|
1 | 6 | 0 |
Kenvue, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Beauty Health Co. has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.121%.
Kenvue, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 4.79%. The Beauty Health Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue, Inc. pays 150.5% of its earnings as a dividend. The Beauty Health Co. pays out -- of its earnings as a dividend.
Kenvue, Inc. quarterly revenues are $3.8B, which are larger than The Beauty Health Co. quarterly revenues of $70.7M. Kenvue, Inc.'s net income of $398M is higher than The Beauty Health Co.'s net income of -$11M. Notably, Kenvue, Inc.'s price-to-earnings ratio is 23.13x while The Beauty Health Co.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue, Inc. is 2.21x versus 0.62x for The Beauty Health Co.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2.21x | 23.13x | $3.8B | $398M |
|
SKIN
The Beauty Health Co.
|
0.62x | -- | $70.7M | -$11M |
Solesence, Inc. has a net margin of 10.58% compared to Kenvue, Inc.'s net margin of -7.67%. Kenvue, Inc.'s return on equity of 13.85% beat Solesence, Inc.'s return on equity of 6.62%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
59% | $0.21 | $19.7B |
|
SLSN
Solesence, Inc.
|
23.09% | -$0.02 | $42.4M |
Kenvue, Inc. has a consensus price target of $19.33, signalling upside risk potential of 12.34%. On the other hand Solesence, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kenvue, Inc. has higher upside potential than Solesence, Inc., analysts believe Kenvue, Inc. is more attractive than Solesence, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2 | 11 | 0 |
|
SLSN
Solesence, Inc.
|
0 | 0 | 0 |
Kenvue, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Solesence, Inc. has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.59%.
Kenvue, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 4.79%. Solesence, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue, Inc. pays 150.5% of its earnings as a dividend. Solesence, Inc. pays out -- of its earnings as a dividend.
Kenvue, Inc. quarterly revenues are $3.8B, which are larger than Solesence, Inc. quarterly revenues of $14.6M. Kenvue, Inc.'s net income of $398M is higher than Solesence, Inc.'s net income of -$1.1M. Notably, Kenvue, Inc.'s price-to-earnings ratio is 23.13x while Solesence, Inc.'s PE ratio is 128.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue, Inc. is 2.21x versus 2.07x for Solesence, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2.21x | 23.13x | $3.8B | $398M |
|
SLSN
Solesence, Inc.
|
2.07x | 128.57x | $14.6M | -$1.1M |
Waldencast Plc has a net margin of 10.58% compared to Kenvue, Inc.'s net margin of --. Kenvue, Inc.'s return on equity of 13.85% beat Waldencast Plc's return on equity of -5.64%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
59% | $0.21 | $19.7B |
|
WALD
Waldencast Plc
|
-- | -- | $896.6M |
Kenvue, Inc. has a consensus price target of $19.33, signalling upside risk potential of 12.34%. On the other hand Waldencast Plc has an analysts' consensus of $3.20 which suggests that it could grow by 68.42%. Given that Waldencast Plc has higher upside potential than Kenvue, Inc., analysts believe Waldencast Plc is more attractive than Kenvue, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2 | 11 | 0 |
|
WALD
Waldencast Plc
|
3 | 3 | 0 |
Kenvue, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Waldencast Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Kenvue, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 4.79%. Waldencast Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue, Inc. pays 150.5% of its earnings as a dividend. Waldencast Plc pays out -- of its earnings as a dividend.
Kenvue, Inc. quarterly revenues are $3.8B, which are larger than Waldencast Plc quarterly revenues of --. Kenvue, Inc.'s net income of $398M is higher than Waldencast Plc's net income of --. Notably, Kenvue, Inc.'s price-to-earnings ratio is 23.13x while Waldencast Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue, Inc. is 2.21x versus 0.78x for Waldencast Plc. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
KVUE
Kenvue, Inc.
|
2.21x | 23.13x | $3.8B | $398M |
|
WALD
Waldencast Plc
|
0.78x | -- | -- | -- |
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.